Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24weeks of treatment

DSpace Repository

Efficacy and safety of telaprevir (TVR) triple therapy in a 'real-life' cohort of 102 patients with HCV genotype 1: interim analysis after 24weeks of treatment

Author: Werner, C. R.; Franz, C.; Egetemeyr, D. P.; Janke-Maier, P.; Malek, N. P.; Lauer, U. M.; Berg, C. P.
Tübinger Autor(en):
Werner, Christoph R.
Franz, Christoph
Egetemeyr, Daniel
Janke-Maier, Petra
Malek, Nisar Peter
Lauer, Ulrich Manfred
Berg, Christoph Peter
Published in: Journal of Viral Hepatitis (2014), Bd. 21, H. 5, S. 333-340
Verlagsangabe: Wiley - Blackwell
Language: English
Full text: http://dx.doi.org/10.1111/jvh.12145
ISSN: 1352-0504
DDC Classifikation: 610 - Medicine and health
570 - Life sciences; biology
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)